Search results for "From ACP Journal Club"


 
Results 1 - 10 of about 54 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In symptomatic adults undergoing high-resolution manometry, long-term opioid use was linked to esophageal dysmotility

The results of a recent meta-analysis highlight the need for clinicians to widen their perspective on the risks of opioids to include both upper and lower GI motility disorders, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/12/22/8.htm
22 Dec 2023

In persons aged ≥45 y, the mt-sRNA test had 94% sensitivity for colorectal cancer and 46% for advanced adenomas

The results of the industry-funded study support the use of the multitarget stool RNA (mt-sRNA) test for screening, but better adherence will be needed, and it is unclear whether the new test offers any advantages over current stool DNA testing, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/02/23/6.htm
23 Feb 2024

In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo

An ACP Journal Club commentary said the high-quality randomized trial provides pragmatic guidance on amitriptyline dosing in patients with irritable bowel syndrome (IBS), as well as additional support for the drug as an option in primary care after first-line therapies fail.
https://gastroenterology.acponline.org/archives/2024/02/23/7.htm
23 Feb 2024

In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk

While the FDA has now approved risankizumab for adults with moderate to severe Crohn disease, understanding of the drug's role in relation to other biologic therapies is limited by broad exclusion criteria in randomized controlled trials, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/10/28/10.htm
28 Oct 2022

In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk

The benefits of upadacitinib need to be weighed against individual patients' risk profiles, but the drug is an important step forward in treating Crohn disease, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/09/22/9.htm
22 Sep 2023

ACG-CAG provided suggestions for periendoscopic management of anticoagulants and antiplatelets

The recommendations from the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG), particularly those for withholding antithrombotics before planned endoscopic procedures, require individualized decision making with multidisciplinary input, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2022/07/22/7.htm
22 Jul 2022

Aspirin use is associated with reduced risk for hepatocellular carcinoma

The findings of a recent meta-analysis provide support for an association between aspirin use and reduced risk for hepatocellular carcinoma but do not warrant use of aspirin as prophylaxis, and more research is needed, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2022/07/22/8.htm
22 Jul 2022

In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events

Given their overall safety and convenience, etrasimod and other oral sphingosine-1-phosphate receptor modulators can be considered as first-line therapy in clinically appropriate patients with ulcerative colitis (UC) who do not respond to 5-aminosalicylic acid medications, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/07/28/7.htm
28 Jul 2023

Cholecystectomy reduced major complications vs catheter drainage in high-risk patients with acute cholecystitis

A Dutch trial showed that older patients without life-threatening comorbidities may benefit from early surgical intervention, but the results would be more generalizable if the study had included patients from a broader age range, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2019/03/22/7.htm
22 Mar 2019

In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response

Bezafibrate is currently unavailable in the U.S., but fenofibrate can be offered off-label in these patients with close monitoring of adverse effects, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2018/10/26/8.htm
26 Oct 2018

Result Page: Prev   1   2   3   4   5   6   Next